Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
NASDAQ_Logo

Articles and Videos

Loading...
May 17, 2022
The Dales Report: InMed Pharmaceuticals: Commercializing The Development Of Rare Cannabinoids For The Wellness Market
Shadd Dales of The Dales Report interviews InMed CEO, Eric A. Adams, about the rare cannabinoid market and being able to manufacture rare cannabinoids like...
Read More
April 28, 2022
Edison: Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids
InMed featured in this article about the different cannabinoid manufacturing technologies that are shaping the industry. The article by Edison also talks about the cannabinoid...
Read More
April 28, 2022
Fly exclusive interview with CEO Eric Adams
Leading digital financial news publisher "The Fly" gets an update on the launch of InMed's rare cannabinoid products and progress of our programs from CEO Eric A....
Read More
April 11, 2022
Empowered Patient Podcast: Manufacturing Bioidentical Rare Cannabinoids to Treat Glaucoma and Rare Skin Disease with Eric Adams InMed Pharmaceuticals
Empowered Patient Podcast Host Karen Jagoda speaks with InMed CEO Eric A. Adams about the company's cannabinol programs in glaucoma and epidermolysis bullosa. Excerpt: Eric...
Read More
April 6, 2022
Fireside Chat with Roth Capital: InMed’s CEO, Eric A. Adams Sits Down with Roth Analyst Scott Henry
At the 2022 Roth Conference in California, InMed's CEO, Eric A. Adams, sat down with Roth Capital Analyst Scott R. Henry in a fireside chat....
Read More
April 4, 2022
Forbes Health: What is CBN?
Forbes reporter Lauren Silva dives into the science behind rare cannabinoid, cannabinol, also known as CBN. The article features clinical and preclinical research conducted on...
Read More
« Previous 1 2 3 4 5 … 16 Next »

Novel Cannabinoid Analogs

Our patentable cannabinoid analogs can be slightly modified to target specific pharmacological properties.
Learn More

Board of Directors

Learn More

Scientific Advisory Board

Learn More

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.
SIGN UP
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

  • Cannabinoids in Development
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Neurodegenerative Disease
  • Novel Cannabinoid Analogs

MANUFACTURING

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing
  • BayMedica Cannabinoid Biosynthesis
  • Rare Cannabinoid Ingredients

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Events Calendar
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

Name*
Consent